1 day ago · Novo Nordisk already makes semaglutide, a tablet used to treat patients with Type 2 diabetes. However, they are seeking regulatory approval for the tablet to be used as a weight loss treatment ...

Dec 20, 2024 · Lilly’s Zepbound, approved in November 2023 as the Indiana-based drug giant’s answer to Novo Nordisk’s Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its...

Novo had said it expected patients to lose at least 25% of their body weight on CagriSema, but in a Phase 3 trial, patients only lost 22.7%. On Wednesday, Jørgensen said that Novo remains ...

Dec 20, 2024 · Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating ...

Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on...

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major ...

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Learn how Wegovy® (semaglutide) can help adults with obesity or excess weight with weight related conditions. Read Important Safety and Prescribing Info, including Boxed Warning.

Jun 4, 2021 · Despite the best efforts to lose weight, many people with obesity struggle to achieve and maintain weight loss due to physiological responses that favour weight regain,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “The unprecedented weight loss for an anti-obesity medication marks a new era in the ...

Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday at the European...